Global Liposome Drug Delivery Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Liposome Drug Delivery Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
Liposome Drug Delivery report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Liposome Drug Delivery market is projected to reach US$ 8760.1 million in 2034, increasing from US$ 3734 million in 2022, with the CAGR of 12.8% during the period of 2024 to 2034. Demand from Fungal Infection Therapy and Cancer & Tumor Therapy are the major drivers for the industry.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liposome Drug Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Liposome Drug Delivery market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Liposome Drug Delivery, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Liposome Drug Delivery industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Liposome Drug Delivery in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Liposome Drug Delivery introduction, etc. Liposome Drug Delivery Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Liposome Drug Delivery market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Liposome Drug Delivery report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Liposome Drug Delivery market is projected to reach US$ 8760.1 million in 2034, increasing from US$ 3734 million in 2022, with the CAGR of 12.8% during the period of 2024 to 2034. Demand from Fungal Infection Therapy and Cancer & Tumor Therapy are the major drivers for the industry.
Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liposome Drug Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Liposome Drug Delivery market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Liposome Drug Delivery, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Liposome Drug Delivery industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Liposome Drug Delivery in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Liposome Drug Delivery introduction, etc. Liposome Drug Delivery Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Liposome Drug Delivery market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices